Chronic DLL4 blockade induces vascular neoplasms

Nature

Volumn 463, Issue 7282, 2010, Pages

  Yan, Minhong ^a   Callahan, Christopher A ^a   Beyer, Joseph C ^a   Allamneni, Krishna P ^a   Zhang, Gu ^a   Ridgway, John Brady ^a   Niessen, Kyle ^a   Plowman, Greg D ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIBENZAZEPINE DERIVATIVE; GALECTIN 1; MEMBRANE PROTEIN; NOTCH RECEPTOR; PROTEIN DELTA LIKE 4; PROTEIN EGFL7; SCLEROPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER THERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; GENE EXPRESSION; HISTOPATHOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; VASCULAR TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACACA FASCICULARIS; MEMBRANE PROTEINS; MICE; RATS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; VASCULAR NEOPLASMS;

EID: 76749157186     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08751     Document Type: Note

References (9)

1. Ridgway, J., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006).
2. Noguera-Troise, I., et al. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 444, 1032-1037 (2006).
3. Li, J. L. & Harris, A. L. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front. Biosci. 14, 3094-3110 (2009).
4. Hicklin, D. J. Promoting angiogenesis to a fault. Nature Biotechnol. 25, 300-302 (2007).
5. Seton-Rogers, S. Tumour suppressors: Different roads to inactivation. Nature Rev. Cancer 7, 72 (2007).
6. ClinicalTrials.gov. A multiple-ascending-dose study of the safety and tolerability of REGN421 in patients with advanced solid malignancies http://clinicaltrials.gov/ ct2/show/NCT00871559; (Accessed 7 January 2010).
7. ClinicalTrials.gov. A phase 1 dose escalation study of OMP-21M18 in subjects with solid tumors http://clinicaltrials.gov/ct2/show/NCT00744562 (Accessed 7 January 2010).
8. Schmidt, M., et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 134, 2913-2923 (2007).
9. Hsieh, S. H., et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27, 3746-3753 (2008).